Cargando…

Applications of a novel tumor-grading-metastasis staging system for pancreatic neuroendocrine tumors: An analysis of surgical patients from a Chinese institution

The ability to stratify patients with pancreatic neuroendocrine tumors (p-NETs) into prognostic groups has been hindered by the absence of a commonly accepted staging system. Both the 7th tumor-node-metastasis (TNM) staging guidelines by the American Joint Committee on Cancer (AJCC) and the 2010 gra...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Min, Tan, Chun-Lu, Zhang, Yi, Ke, Neng-Wen, Zeng, Lin, Li, Ang, Zhang, Hao, Xiong, Jun-Jie, Guo, Zi-Heng, Tian, Bo-Le, Liu, Xu-Bao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4956818/
https://www.ncbi.nlm.nih.gov/pubmed/27428224
http://dx.doi.org/10.1097/MD.0000000000004213
_version_ 1782444084279902208
author Yang, Min
Tan, Chun-Lu
Zhang, Yi
Ke, Neng-Wen
Zeng, Lin
Li, Ang
Zhang, Hao
Xiong, Jun-Jie
Guo, Zi-Heng
Tian, Bo-Le
Liu, Xu-Bao
author_facet Yang, Min
Tan, Chun-Lu
Zhang, Yi
Ke, Neng-Wen
Zeng, Lin
Li, Ang
Zhang, Hao
Xiong, Jun-Jie
Guo, Zi-Heng
Tian, Bo-Le
Liu, Xu-Bao
author_sort Yang, Min
collection PubMed
description The ability to stratify patients with pancreatic neuroendocrine tumors (p-NETs) into prognostic groups has been hindered by the absence of a commonly accepted staging system. Both the 7th tumor-node-metastasis (TNM) staging guidelines by the American Joint Committee on Cancer (AJCC) and the 2010 grading classifications by the World Health Organization (WHO) were validated to be unsatisfactory. We aim to evaluate the feasibility of combining the latest AJCC and WHO criteria to devise a novel tumor-grading-metastasis (TGM) staging system. We also sought to examine the stage-specific survival rates and the prognostic value of this new TGM system for p-NETs. Data of 120 patients with surgical resection and histopathological diagnosis of p-NETs from January 2004 to February 2014 in our institution were retrospectively collected and analyzed. Based on the AJCC and WHO criteria, we replaced the stage N0 and N1 with stage G(a) (NET G1 and NET G2) and G(b) (NET G3 and MANEC) respectively, without changes of the definition of T or M stage. The present novel TGM staging system was grouped as follows: stage I was defined as T1–2, G(a), M0; stage II as T3, G(a), M0 or as T1–3, G(b), M0; stage III as T4, G(a–b), M0 and stage IV as any T, M1. The new TGM staging system successfully distributed 55, 42, 12, and 11 eligible patients in stage I to IV, respectively. Differences of survival compared stage I with III and IV for patients with p-NETs were both statistically significant (P < 0.001), as well as those of stage II with III and IV (P < 0.001). Patients in stage I showed better a survival than those in stage II, whereas difference between stages III and IV was not notable (P = 0.001, P = 0.286, respectively). In multivariate models, when the TGM staging system was evaluated in place of the individual T, G, and M variables, this new criteria were proven to be an independent predictor of survival for surgically resected p-NETs (P < 0.05). Stratifying patients well, the current proposed TGM staging system was predictive for overall survival of p-NETs and could be more widely applied in clinical practice.
format Online
Article
Text
id pubmed-4956818
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-49568182016-08-02 Applications of a novel tumor-grading-metastasis staging system for pancreatic neuroendocrine tumors: An analysis of surgical patients from a Chinese institution Yang, Min Tan, Chun-Lu Zhang, Yi Ke, Neng-Wen Zeng, Lin Li, Ang Zhang, Hao Xiong, Jun-Jie Guo, Zi-Heng Tian, Bo-Le Liu, Xu-Bao Medicine (Baltimore) 5700 The ability to stratify patients with pancreatic neuroendocrine tumors (p-NETs) into prognostic groups has been hindered by the absence of a commonly accepted staging system. Both the 7th tumor-node-metastasis (TNM) staging guidelines by the American Joint Committee on Cancer (AJCC) and the 2010 grading classifications by the World Health Organization (WHO) were validated to be unsatisfactory. We aim to evaluate the feasibility of combining the latest AJCC and WHO criteria to devise a novel tumor-grading-metastasis (TGM) staging system. We also sought to examine the stage-specific survival rates and the prognostic value of this new TGM system for p-NETs. Data of 120 patients with surgical resection and histopathological diagnosis of p-NETs from January 2004 to February 2014 in our institution were retrospectively collected and analyzed. Based on the AJCC and WHO criteria, we replaced the stage N0 and N1 with stage G(a) (NET G1 and NET G2) and G(b) (NET G3 and MANEC) respectively, without changes of the definition of T or M stage. The present novel TGM staging system was grouped as follows: stage I was defined as T1–2, G(a), M0; stage II as T3, G(a), M0 or as T1–3, G(b), M0; stage III as T4, G(a–b), M0 and stage IV as any T, M1. The new TGM staging system successfully distributed 55, 42, 12, and 11 eligible patients in stage I to IV, respectively. Differences of survival compared stage I with III and IV for patients with p-NETs were both statistically significant (P < 0.001), as well as those of stage II with III and IV (P < 0.001). Patients in stage I showed better a survival than those in stage II, whereas difference between stages III and IV was not notable (P = 0.001, P = 0.286, respectively). In multivariate models, when the TGM staging system was evaluated in place of the individual T, G, and M variables, this new criteria were proven to be an independent predictor of survival for surgically resected p-NETs (P < 0.05). Stratifying patients well, the current proposed TGM staging system was predictive for overall survival of p-NETs and could be more widely applied in clinical practice. Wolters Kluwer Health 2016-07-18 /pmc/articles/PMC4956818/ /pubmed/27428224 http://dx.doi.org/10.1097/MD.0000000000004213 Text en Copyright © 2016 the Author(s). Published by Wolters Kluwer Health, Inc. All rights reserved. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle 5700
Yang, Min
Tan, Chun-Lu
Zhang, Yi
Ke, Neng-Wen
Zeng, Lin
Li, Ang
Zhang, Hao
Xiong, Jun-Jie
Guo, Zi-Heng
Tian, Bo-Le
Liu, Xu-Bao
Applications of a novel tumor-grading-metastasis staging system for pancreatic neuroendocrine tumors: An analysis of surgical patients from a Chinese institution
title Applications of a novel tumor-grading-metastasis staging system for pancreatic neuroendocrine tumors: An analysis of surgical patients from a Chinese institution
title_full Applications of a novel tumor-grading-metastasis staging system for pancreatic neuroendocrine tumors: An analysis of surgical patients from a Chinese institution
title_fullStr Applications of a novel tumor-grading-metastasis staging system for pancreatic neuroendocrine tumors: An analysis of surgical patients from a Chinese institution
title_full_unstemmed Applications of a novel tumor-grading-metastasis staging system for pancreatic neuroendocrine tumors: An analysis of surgical patients from a Chinese institution
title_short Applications of a novel tumor-grading-metastasis staging system for pancreatic neuroendocrine tumors: An analysis of surgical patients from a Chinese institution
title_sort applications of a novel tumor-grading-metastasis staging system for pancreatic neuroendocrine tumors: an analysis of surgical patients from a chinese institution
topic 5700
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4956818/
https://www.ncbi.nlm.nih.gov/pubmed/27428224
http://dx.doi.org/10.1097/MD.0000000000004213
work_keys_str_mv AT yangmin applicationsofanoveltumorgradingmetastasisstagingsystemforpancreaticneuroendocrinetumorsananalysisofsurgicalpatientsfromachineseinstitution
AT tanchunlu applicationsofanoveltumorgradingmetastasisstagingsystemforpancreaticneuroendocrinetumorsananalysisofsurgicalpatientsfromachineseinstitution
AT zhangyi applicationsofanoveltumorgradingmetastasisstagingsystemforpancreaticneuroendocrinetumorsananalysisofsurgicalpatientsfromachineseinstitution
AT kenengwen applicationsofanoveltumorgradingmetastasisstagingsystemforpancreaticneuroendocrinetumorsananalysisofsurgicalpatientsfromachineseinstitution
AT zenglin applicationsofanoveltumorgradingmetastasisstagingsystemforpancreaticneuroendocrinetumorsananalysisofsurgicalpatientsfromachineseinstitution
AT liang applicationsofanoveltumorgradingmetastasisstagingsystemforpancreaticneuroendocrinetumorsananalysisofsurgicalpatientsfromachineseinstitution
AT zhanghao applicationsofanoveltumorgradingmetastasisstagingsystemforpancreaticneuroendocrinetumorsananalysisofsurgicalpatientsfromachineseinstitution
AT xiongjunjie applicationsofanoveltumorgradingmetastasisstagingsystemforpancreaticneuroendocrinetumorsananalysisofsurgicalpatientsfromachineseinstitution
AT guoziheng applicationsofanoveltumorgradingmetastasisstagingsystemforpancreaticneuroendocrinetumorsananalysisofsurgicalpatientsfromachineseinstitution
AT tianbole applicationsofanoveltumorgradingmetastasisstagingsystemforpancreaticneuroendocrinetumorsananalysisofsurgicalpatientsfromachineseinstitution
AT liuxubao applicationsofanoveltumorgradingmetastasisstagingsystemforpancreaticneuroendocrinetumorsananalysisofsurgicalpatientsfromachineseinstitution